Even while following best practices, surface exposures of hazardous drugs (HDs) are high and numerous. Thus, it is important to develop new products to reduce the surface contamination of HDs. Hazardous Drug Clean (HDClean™) was developed to decontaminate and remove HDs from various types of surfaces and overcome the problems associated with other cleaning products.
Methods
HDClean was evaluated to remove mock surface exposures of HDs (docetaxel, paclitaxel, ifosfamide, cyclophosphamide, 5-FU, and cisplatin) from various types of surfaces. In two separate cancer centers, studies were performed to evaluate HDClean in reducing surface contamination of HDs in the pharmacy departments where no closed system transfer device (CSTD) was used. In a third cancer center, studies were performed comparing the effectiveness of a CSTD + Surface Safe compared with CSTD + HDClean to remove HDs.
Results
HDClean was able to completely remove mock exposures of a wide range of HDs from various surfaces (4 and 8 sq ft areas). Daily use of HDClean was equal to or more effective in reducing surface contamination of HDs in two pharmacies compared with a CSTD. HDClean was significantly more effective in removing HDs, especially cisplatin, compared with Surface Safe and does not have the problems associated with decontamination solutions that contain sodium hypochlorite.
Conclusion
These studies support HDClean as an effective decontaminating product, that HDClean is more effective than Surface Safe in removing HDs and is equal to or more effective than CSTD in controlling HD surface exposures.
Centers for Disease Control and Prevention. Proposed additions and deletions to the NIOSH Hazardous Drug List 2014. 2014.
2.
SkovTMaarupBOlsenJ. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med1992; 49: 855–861.
3.
LevinLIHollyEASewardJP. Bladder cancer in a 39-year-old female pharmacist. J Natl Cancer Inst1993; 85: 1089–1091.
4.
McAbeeRRGallucciBJCheckowayH. Adverse reproductive outcomes and occupational exposures among nurses: an investigation of multiple hazardous exposures. AAOHN J1993; 41: 110–119.
5.
ValanisBGVollmerWMLabuhnKT. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm1993; 50: 455–462.
6.
ValanisBGVollmerWMLabuhnKT. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs1993; 16: 288–295.
7.
ValanisBVollmerWMSteeleP. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med1999; 41: 632–638.
8.
LorenteCCordierSBergeretA. Maternal occupational risk factors for oral clefts. Occupational Exposure and Congenital Malformation Working Group. Scand J Work Environ Health2000; 26: 137–145.
9.
FransmanWRoeleveldNPeelenS. Nurses with dermal exposure to antineoplastic drugs: Reproductive outcomes. Epidemiology2007; 18: 112–119.
10.
McDiarmidMAOliverMSRothTS. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J Occup Environ Med2010; 52: 1028–1034.
11.
Xie J, Wang J, Li H, et al. Epidemiological study of effect of occupational exposure to antineoplastic drugs on reproductive outcome in nurses. Cin J Ind Hyg Occup Dis 2001; 19(2): 87–90.
12.
NguyenTVTheissJCMatneyTS. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res1982; 42: 4792–4796.
13.
ConnorTHDeBordDGPrettyJR. Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J Occup Environ Med2010; 52: 1019–1027.
14.
American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 1990; 47: 1033–1049.
15.
National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, 2004.
16.
US Pharmacopeia U. Guidebook to pharmaceutical compounding: sterile preparations. Rockville, MD: United States Pharmacopeia, 2008.
17.
SchierlRHerwigAPfallerA. Surface contamination of antineoplastic drug vials: comparison of unprotected and protected vials. Am J Health Syst Pharm2010; 67: 428–429.
18.
ConnorTHSessinkPJHarrisonBR. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health Syst Pharm2005; 62: 475–484.
19.
ClarkBASessinkPJ. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents. J Oncol Pharm Pract2013; 19: 99–104.
20.
SessinkPJTrahanJCoyneJW. Reduction in surface contamination with cyclophosphamide in 30 US hospital pharmacies following implementation of a closed-system drug transfer device. Hosp Pharm2013; 48: 204–212.
21.
SessinkPJConnorTHJorgensonJA. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Pract2011; 17: 39–48.
22.
ZockMDSoefjeSRickabaughK. Evaluation of surface contamination with cyclophosphamide following simulated hazardous drug preparation activities using two closed-system products. J Oncol Pharm Pract2011; 17: 49–54.
23.
ConnorTHAndersonRWSessinkPJ. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health Syst Pharm2002; 59: 68–72.
24.
YoshidaJTeiGMochizukiC. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Ann Occup Hyg2009; 53: 153–160.
25.
MiyakeTIwamotoTTanimuraM. Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013; 2: 273–273.
26.
WickCSlawsonMHJorgensonJA. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm2003; 60: 2314–2320.
27.
YoshidaJKodaSNishidaS. Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. J Oncol Pharm Pract2011; 17: 29–38.
28.
FavierBLabrosseHGilles-AfchainL. The PhaSeal(R) system: impact of its use on workplace contamination and duration of chemotherapy preparation. J Oncol Pharm Pract2012; 18: 37–45.
29.
US Pharmacopeia USP 800. Hazardous drugs—Handling in healthcare settings. 2014.
30.
DorrRTAlbertsDS. Topical absorption and inactivation of cytotoxic anticancer agents in vitro. Cancer1992; 70: 983–987.
31.
EkhartCGebretensaeARosingH. Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci2007; 854: 345–349.
32.
ZhouJGaoSZhangF. Liquid chromatography-tandem mass spectrometry method for simultaneous determination of seven commonly used anticancer drugs in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci2012; 906: 1–8.
33.
ZhangWDutschmanGELiX. Quantitation of paclitaxel and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci2011; 879: 2018–2022.
34.
Licea-PerezHWangSBowenC. Development of a sensitive and selective LC-MS/MS method for the determination of alpha-fluoro-beta-alanine, 5-fluorouracil and capecitabine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci2009; 877: 1040–1046.
35.
Garcia-AcASeguraPAViglinoL. Comparison of APPI, APCI and ESI for the LC-MS/MS analysis of bezafibrate, cyclophosphamide, enalapril, methotrexate and orlistat in municipal wastewater. J Mass Spectrom2011; 46: 383–390.
36.
KarginovaOSiegelMBVan SwearingenAE. Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple-negative breast cancer. Mol Cancer Ther2015; 14: 920–930.
37.
GantaSSinghAKulkarniP. EGFR targeted theranostic nanoemulsion for image-guided ovarian cancer therapy. Pharm Res2015; 32: 2753–2763.
